DEFINITIONS

In this document, unless the context otherwise requires, the following terms shall have the meanings set forth below. Certain technical terms are explained in "Glossary."

"Accountants' Report"	the accountants' report of our Company for the Track Record Period, as included in Appendix I to this document
"Affiliate"	with respect to any specified person, any other person, directly or indirectly, controlling or controlled by or under direct or indirect common control with such specified person
"AFRC"	Accounting and Financial Reporting Council of Hong Kong
"Articles of Association" or "Articles"	the articles of association of our Company adopted on January 26, 2026 with effect from the [REDACTED], as amended, supplemented, or otherwise modified from time to time, a summary of which is set out in "Appendix III — Summary of Articles of Association" to this document
"associate(s)"	has the meaning ascribed thereto under the Listing Rules
"Audit Committee"	the audit committee of the Board
"Board" or "Board of Directors"	the board of Directors of our Company
"business day"	any day (other than a Saturday, Sunday or public holiday in Hong Kong) on which banks in Hong Kong are generally open for normal banking business
[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]
"China" or "PRC"	the People's Republic of China excluding, for the purposes of this document, Hong Kong, Macau and Taiwan Province of the People's Republic of China
"CIC"	China Insights Industry Consultancy Limited, an independent global market research and consulting company
"CIC Report"	the independent industry report prepared by CIC as commissioned by us
"close associate(s)"	has the meaning ascribed thereto under the Listing Rules
"Companies Ordinance"	the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) as amended, supplemented or otherwise modified from time to time

"Companies (Winding Up and Miscellaneous Provisions) Ordinance"	the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Chapter 32 of the Laws of Hong Kong) as amended, supplemented or otherwise modified from time to time
"Company", "our Company", "we", "our" or "us"	Beijing Wehand-Bio Pharmaceutical Co., Ltd. (北京五和博澳藥業股份有限公司), a limited liability company established in the PRC on May 7, 2010 and converted into a joint stock company with limited liability on March 30, 2021, formerly known as Beijing Wehand-Bio Pharmaceutical Technology Development Co., Ltd. (北京五和博澳醫藥科技發展有限公司)
"Company Law" or "PRC Company Law"	the Company Law of the PRC (《中華人民共和國公司法》), as amended, supplemented or otherwise modified from time to time
"Compliance Advisor"	Rainbow Capital (HK) Limited
"Controlling Shareholder(s)"	has the meaning given to it under the Listing Rules and, unless the context otherwise requires, refers to Mr. HUANG Yuesheng, Mr. HU Dingfei, Mr. YU Xiecai, Wehand Tongyuan No.1, Wehand Tongyuan No.2, Wehand Tongyuan No.3, Jiujiang Ruida and Jiujiang Ruihe as further detailed in the section headed in "Relationship with Our Controlling Shareholders" in this document
"Conversion of Unlisted Shares into H Shares"	the conversion of [REDACTED] Unlisted Shares into H Shares on a one-for-one basis upon the completion of [REDACTED]. Filing of such conversion of Unlisted Shares into H shares [has been completed] with the CSRC on [•] and an application for H Shares to be [REDACTED] on the Stock Exchange has been made to the [REDACTED]
"core connected person"	has the meaning ascribed thereto under the Listing Rules
"Core Product"	has the meaning ascribed thereto in Chapter 18A of the Listing Rules; for the purpose of this document, our Core Product refers to WH007, WH006 and WH002
"CSDC"	China Securities Depository and Clearing Co., Ltd. (中國證券登記結算有限責任公司)
"CSRC"	China Securities Regulatory Commission (中國證券監督管理委員會), a regulatory body responsible for the supervision and regulation of the PRC national securities markets
"Director(s)"	the director(s) of our Company
"EIT"	enterprise income tax
"EIT Law"	the Enterprise Income Tax Law of the PRC (《中華人民共和國企業所得稅法》), as amended, supplemented or otherwise modified from time to time

"Extreme Conditions"	extreme conditions as announced by the government of Hong Kong in the case where a super typhoon or other natural disaster of a substantial scale seriously affects the working public's ability to resume work or brings safety concern for a prolonged period
"FDA"	the United States Food and Drug Administration
[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]
"Group", "our Group", "we", "our" or "us"	our Company and our subsidiaries (or our Company and any one or more of our subsidiaries, as the context may require)
"Guangxi Wehand-Bio"	Guangxi Wehand-Bio Pharmaceutical Co., Ltd. (廣西五和博澳藥業有限公司), a limited liability company established in the PRC on April 8, 2014 and a wholly-owned subsidiary of our Company
"Guide for New Listing Applicants" or "Guide"	the Guide for New Listing Applicants issued by the Stock Exchange, as amended, supplemented or otherwise modified from time to time
[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]

DEFINITIONS

[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]
"Hong Kong"	the Hong Kong Special Administrative Region of the People's Republic of China
"Hong Kong dollars" or "HK$"	Hong Kong dollars, the lawful currency of Hong Kong
[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]
"H Share(s)"	ordinary share(s) in the share capital of our Company with a nominal value of RMB1.00 each, which is/are to be [REDACTED] for and paid up in Hong Kong dollars and to be [REDACTED] to [REDACTED] on Stock Exchange
[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]

DEFINITIONS

[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]
"IFRS"	International Financial Reporting Standards, as issued by the International Accounting Standards Board
"IMM"	Institute of Materia Medica, Chinese Academy of Medical Sciences (中國醫學科學院藥物研究所), a research institute focused on drug discovery, pharmacology, and the development of traditional and modern medicines
"Independent Third Party(ies)"	person(s) or company(ies) who/which, to the best of our Directors' knowledge, information and belief, is/are not a connected person of our Company
"Jiujiang Ruida"	Jiujiang Ruida Economic Consulting Center (Limited Partnership) (九江瑞達經濟諮詢中心(有限合夥)) is a limited partnership established under the laws of the PRC on November 16, 2020, and one of our Controlling Shareholders
"Jiujiang Ruihe "	Jiujiang Ruihe Enterprise Management Center (Limited Partnership) (九江瑞和企業管理中心(有限合夥)) is a limited partnership established under the laws of the PRC on August 11, 2020, and one of our Controlling Shareholders
"Jiujiang Ruijin"	Jiujiang Ruijin Information Consulting Center (Limited Partnership) (九江瑞津信息諮詢中心(有限合夥)) is a limited partnership established under the laws of PRC on November 20, 2020, and one of our Share Incentive Platforms
[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]
"Latest Practicable Date"	February 18, 2026, being the latest practicable date for the purpose of ascertaining certain information in this document prior to its publication
[REDACTED]	[REDACTED]

[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]
"Listing Rules"	the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited
"Macau"	the Macau Special Administrative Region of the People's Republic of China
"Macau Wehand-Bio"	Macau Wehand-Bio Pharmaceutical Co. Ltd. (澳門五和博澳藥業有限公司), a company established in Macau on April 16, 2025 and a wholly-owned subsidiary of our Company
"Main Board"	the stock exchange (excluding the option market) operated by the Stock Exchange which is independent from and operates in parallel with GEM of the Stock Exchange
"MOFCOM" or "Ministry of Commerce"	the Ministry of Commerce of the PRC (中華人民共和國商務部) (formerly known as the Ministry of Foreign Trade and Economic Cooperation of the PRC (中華人民共和國對外經濟貿易部))
"NDRC"	the National Development and Reform Commission (中華人民共和國國家發展和改革委員會)
"NMPA"	the National Medical Products Administration of the PRC (國家藥品監督管理局) and its predecessor, the China Food and Drug Administration (國家食品藥品監督管理總局)
"Nomination Committee"	the nomination committee of the Board
[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]

[REDACTED]	[REDACTED]
"PBOC"	the People's Bank of China (中國人民銀行), the central bank of the PRC
"PRC Legal Advisor"	Grandway Law Offices, the legal advisor to the Company as to the laws of the PRC
"Pre-[REDACTED] Investment(s)"	the investment(s) in our Company undertaken by the Pre-[REDACTED] Investors, the details of which are set out in "History, Development and Corporate Structure"
"Pre-[REDACTED] Investor(s)"	the investor(s) as set out in "History, Development and Corporate Structure — Pre-[REDACTED] Investments — Information on Our Pre-[REDACTED] Investors"
[REDACTED]	[REDACTED]
"R&D"	research and development
"Regulation S"	Regulation S under the U.S. Securities Act
"Remuneration Committee"	the remuneration committee of the Board
"RMB" or "Renminbi"	Renminbi, the lawful currency of the PRC
"SAFE"	State Administration of Foreign Exchange of the PRC (中華人民共和國國家外匯管理局)
"SAMR"	State Administration for Market Regulation of the PRC (中華人民共和國國家市場監督管理總局)
"SFC"	the Securities and Futures Commission of Hong Kong
"SFO"	the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong)
"Share(s)"	ordinary share(s) in the capital of our Company with a nominal value of RMB1.00 each, comprising Unlisted Shares and H Shares

DEFINITIONS

"Share Incentive Platform(s)"	the share incentive platforms established for the purpose of implementing the share incentive scheme, namely, Wehand Tongyuan No.1, Wehand Tongyuan No.2, Wehand Tongyuan No. 4, Wehand Tongyuan No.5 and Jiujiang Ruijin
"Shareholder(s)"	holder(s) of our Share(s)
"Sole Sponsor" and [REDACTED]	Huatai Financial Holdings (Hong Kong) Limited
"Sophisticated Investor(s)"	has the meaning ascribed to it under the Chapter 2.3 of the Guide for New Listing Applicants
"STA"	State Taxation Administration (中華人民共和國國家稅務總局)
[REDACTED]	[REDACTED]
"State Council"	the State Council of the PRC (中華人民共和國國務院)
"Stock Exchange" or "Hong Kong Stock Exchange"	The Stock Exchange of Hong Kong Limited, a wholly owned subsidiary of Hong Kong Exchanges and Clearing Limited
"Strategy Committee"	strategy committee of the Board
"subsidiary(ies)"	has the meaning ascribed to it under the Listing Rules
"substantial shareholder(s)"	has the meaning ascribed to it under the Listing Rules
"Takeovers Code"	the Code on Takeovers and Mergers issued by the SFC
"Track Record Period"	the fiscal year ended December 31, 2024 and the nine months ended September 30, 2025
"Trial Measures"	Trial Administrative Measures of Overseas Securities Offering and Listing by Domestic Companies (《境內企業境外發行證券和上市管理試行辦法》) released by the CSRC on February 17, 2023 and took effect on March 31, 2023
[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]
"United States" or "U.S."	the United States of America, its territories, its possessions and all areas subject to its jurisdiction
"Unlisted Share(s)"	ordinary share(s) issued by our Company, with a nominal value of RMB1.00 each, which is/are not listed on any stock exchange

"U.S. dollars" or "US$" or "USD"	United States dollars, the lawful currency of the United States
"U.S. Securities Act"	United States Securities Act of 1933, as amended and supplemented or otherwise modified from time to time, and the rules and regulations promulgated thereunder
"VAT"	value-added tax
"Wehand Dacheng"	Beijing Wehand Dacheng Pharmaceutical Technology Co. Ltd. (北京五和大誠醫藥科技有限公司), a limited liability company established in the PRC on December 20, 2023 and a wholly-owned subsidiary of our Company
"Wehand Tongyuan No.1"	Beijing Wehand Tongyuan No.1 Enterprise Management Center (Limited Partnership) (北京五和同源一號企業管理中心(有限合夥)) is a limited partnership established under the laws of the PRC on January 19, 2020, one of our Controlling Shareholders and one of our Share Incentive Platforms
"Wehand Tongyuan No.2"	Beijing Wehand Tongyuan No.2 Enterprise Management Center (Limited Partnership) (北京五和同源二號企業管理中心(有限合夥)) is a limited partnership established under the laws of PRC on January 12, 2021, one of our Controlling Shareholders and one of our Share Incentive Platforms
"Wehand Tongyuan No.3"	Beijing Wehand Tongyuan No.3 Enterprise Management Center (Limited Partnership) (北京五和同源三號企業管理中心(有限合夥)) is a limited partnership established under the laws of PRC on June 11, 2021, one of our Controlling Shareholders
"Wehand Tongyuan No.4"	Beijing Wehand Tongyuan No.4 Enterprise Management Center (Limited Partnership) (北京五和同源四號企業管理中心(有限合夥)is a limited partnership established under the laws of PRC on June 11, 2021, and one of our Share Incentive Platforms
"Wehand Tongyuan No.5"	Beijing Wehand Tongyuan No.5 Enterprise Management Center (Limited Partnership) (北京五和同源五號企業管理中心(有限合夥)is a limited partnership established under the laws of PRC on December 13, 2021, and one of our Share Incentive Platforms
"Zhejiang Wehand-Bio"	Zhejiang Wehand-Bio Pharmaceutical Technology Co. Ltd., (浙江五和博澳醫藥科技有限公司), a limited liability company established in the PRC on November 12, 2024 and a wholly-owned subsidiary of our Company
"%"	percent

For the purpose of this document, references to "provinces" of China include provinces, municipalities under direct administration of the central government and provincial-level autonomous regions.